Update on Adult Immunizations

References

1. 1.↵
   CDC. Adult vaccination coverage—United States, 2010. MMWR Morb Mortal Wkly Rep 2012;61:66–72.

   OpenUrlPubMed
2. 2.↵
   Infectious Diseases Society of America, Robert Wood Johnson Foundation, Trust for America's Health. Adult immunization: shots to save lives. Washington, DC: Trust for America's Health, the Infectious Diseases Society of America, and the Robert Wood Johnson Foundation; 2010. Available from: http://healthyamericans.org/report/73/adult-immunization-2010. Accessed May 22, 2012.
3. 3.↵
   CDC. Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2011. MMWR Morb Mortal Wkly Rep 2011;60:1128–32.

   OpenUrlPubMed
4. 4.↵
   1. Rhorer J,
   2. Ambrose CS,
   3. Dickinson S,
   4. et al

   . Efficacy of live attenuated influenza vaccine in children: A meta-analysis of nine randomized clinical trials. Vaccine 2009;27:1101–10.

   OpenUrlCrossRefPubMedWeb of Science
5. 5.↵
   1. Monto AS,
   2. Ohmit SE,
   3. Petrie JG,
   4. et al

   . Comparative efficacy of inactivated and live attenuated influenza vaccines. N Engl J Med 2009;361:1260–7.

   OpenUrlCrossRefPubMedWeb of Science
6. 6.↵
   1. Tosh PK,
   2. Boyce TG,
   3. Poland GA

   . Flu myths: dispelling the myths associated with live attenuated influenza vaccine. Mayo Clin Proc 2008;83:77–84.

   OpenUrlCrossRefPubMedWeb of Science
7. 7.↵
   Fluzone [package insert]. Swiftwater, PA: Sanofi Pasteur Inc.; 2011.
8. 8.↵
   World Health Organization. Pneumococcal conjugate vaccine for childhood immunization–WHO position paper. Wkly Epidemiol Rec 2007;82:93–104.

   OpenUrlPubMed
9. 9.↵
   1. Atkinson W,
   2. Wolfe S,
   3. Hamborsky J

   Centers for Disease Control and Prevention. Pneumococcal disease. In: Epidemiology and Prevention of Vaccine-Preventable Diseases. Atkinson W, Wolfe S, Hamborsky J , eds. 12th ed., second printing. Washington DC: Public Health Foundation; 2012:233–48. Available from: http://www.cdc.gov/vaccines/pubs/pinkbook/pneumo.html. Accessed May 22, 2012.
10. 10.↵
    World Health Organization. 23-Valent pneumococcal polysaccharide vaccine. WHO position paper. Wkly Epidemiol Rec 2008;83:373–84.

    OpenUrlPubMed
11. 11.↵
    1. Corrales-Medina VF,
    2. Madjid M,
    3. Musher DM

    . Role of acute infection in triggering acute coronary syndromes. Lancet Infect Dis 2010;10:83–92.

    OpenUrlCrossRefPubMedWeb of Science
12. 12.↵
    1. Vila-Córcoles A

    . Vaccinate your child and save its grandparents from a heart attack? Current perspectives in antipneumococcal vaccination. J Intern Med 2009;266:432–44.

    OpenUrlCrossRefPubMed
13. 13.↵
    1. Hung IFN,
    2. Leung AYM,
    3. Chu DWS,
    4. et al

    . Prevention of acute myocardial infarction and stroke among elderly persons by dual pneumococcal and influenza vaccination: a prospective cohort study. Clin Infect Dis 2010;51:1007–16.

    OpenUrlAbstract/FREE Full Text
14. 14.↵
    1. Nichol KL

    . Pneumococcal vaccination and revaccination in the elderly population. J Infect Dis 2010;201:659–61.

    OpenUrlFREE Full Text
15. 15.↵
    1. Musher DM,
    2. Manoff SB,
    3. McFetridge RD,
    4. et al

    . Antibody persistence 10 years after first and second doses of 23-valent pneumococcal polysaccharide vaccine, and immunogenicity and safety of second and third doses in older adults. Hum Vaccin 2011;7:919–28.

    OpenUrlCrossRefPubMed
16. 16.↵
    1. Hammitt LL,
    2. Bulkow LR,
    3. Singleton RJ,
    4. et al

    . Repeat revaccination with 23-valent pneumococcal polysaccharide vaccine among adults aged 55–74 years living in Alaska: no evidence of hyporesponsiveness. Vaccine 2011;29:2287–95.

    OpenUrlCrossRefPubMedWeb of Science
17. 17.↵
    1. Musher DM,
    2. Sampath R,
    3. Rodriguez-Barradas MC

    . The potential role for protein-conjugate pneumococcal vaccine in adults: what is the supporting evidence? Clin Infect Dis 2011;52:633–40.

    OpenUrlAbstract/FREE Full Text
18. 18.↵
    Specifications Manual, Version 4.0c. Discharges 01/01/2012 to 06/30/2012. Available from: http://www.qualitynet.org/dcs/ContentServer?c=Page&pagename=QnetPublic%2FPage%2FQnetTier4&cid=1228767363466. Accessed May 22, 2012.
19. 19.↵
    1. Harpaz R,
    2. Ortega-Sanchez IR,
    3. Seward JF

    . Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2008;57(RR-5):1–30; quiz CE2–4.

    OpenUrlPubMed
20. 20.↵
    1. Gnann JW,
    2. Whitley RJ

    . Herpes zoster. N Engl J Med 2002;347:340–6.

    OpenUrlCrossRefPubMedWeb of Science
21. 21.↵
    1. Li Q,
    2. Chen N,
    3. Yang J,
    4. et al

    . Antiviral treatment for preventing postherpetic neuralgia. Cochrane Database Syst Rev 2009;(2):CD006866.
22. 22.↵
    Centers for Disease Control and Prevention. Update on herpes zoster vaccine: licensure for persons aged 50 through 59 years. MMWR Morb Mortal Wkly Rep 2011;60:1528.

    OpenUrlPubMed
23. 23.↵
    1. Singh A,
    2. Englund K

    . Q: Who should receive the shingles vaccine? Cleve Clin J Med 2009;76:45–8.

    OpenUrlFREE Full Text
24. 24.↵
    1. Tseng HF,
    2. Smith N,
    3. Harpaz R,
    4. Bialek SR,
    5. Sy LS,
    6. Jacobsen SJ

    . Herpes zoster vaccine in older adults and the risk of subsequent herpes zoster disease. JAMA 2011;305:160–6.

    OpenUrlCrossRefPubMedWeb of Science
25. 25.↵
    1. MacIntyre C,
    2. Egerton T,
    3. McCaughey M,
    4. et al

    . Concomitant administration of zoster and pneumococcal vaccines in adults ≥60 years old. Abstract presented at: ICAAC/IDSA 2008 Joint Meeting, October 25–28, 2008, Washington, DC.
26. 26.↵
    Centers for Disease Control and Prevention. Vaccines and preventable diseases: herpes zoster vaccination for health care professionals. 2011. Available at: http://www.cdc.gov/vaccines/vpd-vac/shingles/hcp-vaccination.htm. Accessed February 3, 2012.
27. 27.↵
    1. Tseng HF,
    2. Smith N,
    3. Sy LS,
    4. Jacobsen SJ

    . Evaluation of the incidence of herpes zoster after concomitant administration of zoster vaccine and polysaccharide pneumococcal vaccine. Vaccine 2011;29:3628–32.

    OpenUrlCrossRefPubMedWeb of Science
28. 28.↵
    1. Markowitz LE,
    2. Dunne EF,
    3. Saraiya M,
    4. Lawson HW,
    5. Chesson H,
    6. Unger ER

    . Quadrivalent human papillomavirus vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2007;56(RR-2):1–24.

    OpenUrlPubMed
29. 29.↵
    1. Atkinson W,
    2. Wolfe S,
    3. Hamborsky J

    Centers for Disease Control and Prevention. Human papillomavirus. In: Epidemiology and Prevention of Vaccine-Preventable Diseases. Atkinson W, Wolfe S, Hamborsky J , eds. 12th ed., second printing. Washington DC: Public Health Foundation; 2012:139–50. Available from: http://www.cdc.gov/vaccines/pubs/pinkbook/hpv.html. Accessed May 22, 2012.
30. 30.↵
    1. D'Souza G,
    2. Dempsey A

    . The role of HPV in head and neck cancer and review of the HPV vaccine. Prev Med 2011;53(Suppl 1):S5–11.

    OpenUrlCrossRefPubMed
31. 31.↵
    1. Broomall E,
    2. Reynolds S,
    3. Jacobson R

    . Epidemiology, clinical manifestations, and recent advances in vaccination against human papillomavirus. Postgrad Med 2010;122:121–9.

    OpenUrlCrossRefPubMed
32. 32.↵
    Centers for Disease Control and Prevention. FDA licensure of bivalent human papillomavirus vaccine (HPV2, Cervarix) for use in females and updated HPV vaccination recommendations from the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2010;59:626–9.

    OpenUrlPubMed
33. 33.↵
    1. Gillison ML

    . Human papillomavirus-associated head and neck cancer is a distinct epidemiologic, clinical, and molecular entity. Semin Oncol 2004;31:744–54.

    OpenUrlCrossRefPubMedWeb of Science
34. 34.↵
    1. Kreimer AR,
    2. Clifford GM,
    3. Boyle P,
    4. Franceschi S

    . Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systematic review. Cancer Epidemiol Biomarkers Prev 2005;14:467–75.

    OpenUrlAbstract/FREE Full Text
35. 35.↵
    1. Chaturvedi AK,
    2. Engels EA,
    3. Pfeiffer RM,
    4. et al

    . Human papillomavirus and rising oropharyngeal cancer incidence in the united states. J Clin Oncol 2011;29:4294–301.

    OpenUrlAbstract/FREE Full Text
36. 36.↵
    1. D'Souza G,
    2. Kreimer AR,
    3. Viscidi R,
    4. et al

    . Case-control study of human papillomavirus and oropharyngeal cancer. N Engl J Med 2007;356:1944–56.

    OpenUrlCrossRefPubMedWeb of Science
37. 37.↵
    1. Dufour X,
    2. Beby-Defaux A,
    3. Agius G,
    4. Lacau St Guily J

    . HPV and head and neck cancer. Eur Ann Otorhinolaryngol Head Neck Dis 2012;129:26–31.

    OpenUrlPubMed
38. 38.↵
    1. Gillison ML,
    2. Broutian T,
    3. Pickard RKL,
    4. et al

    . Prevalence of oral HPV infection in the United States, 2009–2010. JAMA 2012;307:693–703.

    OpenUrlCrossRefPubMedWeb of Science
39. 39.↵
    1. Gillison ML

    . Human papillomavirus-related diseases: oropharynx cancers and potential implications for adolescent HPV vaccination. J Adolesc Health 2008;43(4 Suppl):S52–60.

    OpenUrlCrossRefPubMedWeb of Science
40. 40.↵
    1. Cherry JD

    . The epidemiology of pertussis: a comparison of the epidemiology of the disease pertussis with the epidemiology of Bordetella pertussis infection. Pediatrics 2005;115:1422–7.

    OpenUrlAbstract/FREE Full Text
41. 41.↵
    1. Atkinson W,
    2. Wolfe S,
    3. Hamborsky J

    Centers for Disease Control and Prevention. Pertussis. In: Epidemiology and Prevention of Vaccine-Preventable Diseases. Atkinson W, Wolfe S, Hamborsky J , eds. 12th ed., second printing. Washington DC: Public Health Foundation; 2012:215–32. Available from: http://www.cdc.gov/vaccines/pubs/pinkbook/pert.html. Accessed May 22, 2012.
42. 42.↵
    1. Wendelboe AM,
    2. Van Rie A,
    3. Salmaso S,
    4. Englund JA

    . Duration of immunity against pertussis after natural infection or vaccination. Pediatr Infect Dis J 2005;24(5 Suppl):S58–61.

    OpenUrlCrossRefPubMed
43. 43.↵
    Centers for Disease Control and Prevention. Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine (Tdap) in pregnant women and persons who have or anticipate having close contact with an infant aged <12 months—Advisory Committee on Immunization Practices (ACIP), 2011. MMWR Morb Mortal Wkly Rep 2011;60:1424–6.

    OpenUrlPubMed
44. 44.↵
    1. Atkinson W,
    2. Kroger A

    . IAC Express 2010. Issue number 871: June 2, 2010. Ask the experts. Available from: http://www.immunize.org/express/issue871.asp. Accessed January 15, 2012.
45. 45.↵
    Centers for Disease Control and Prevention. Immunization of health-care personnel: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2011;60(RR-7):1–45.

    OpenUrlPubMed
46. 46.↵
    Centers for Disease Control and Prevention. Updated recommendation from the Advisory Committee on Immunization Practices (ACIP) for revaccination of persons at prolonged increased risk for meningococcal disease. MMWR Morb Mortal Wkly Rep 2009;58:1042–3.

    OpenUrlPubMed
47. 47.↵
    Centers for Disease Control and Prevention. Updated recommendations for use of meningococcal conjugate vaccines—Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Morb Mortal Wkly Rep 2011;60:72–6.

    OpenUrlPubMed
48. 48.↵
    1. Marin M,
    2. Güris D,
    3. Chaves SS,
    4. Schmid S,
    5. Seward JF

    . Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2007;56(RR-4):1–40.

    OpenUrlPubMed
49. 49.↵
    Centers for Disease Control and Prevention. Notice to readers: FDA approval of an alternate dosing schedule for a combined hepatitis A and B vaccine (Twinrix). MMWR Morb Mortal Wkly Rep 2007;56:1057.

    OpenUrl
50. 50.↵
    Centers for Disease Control and Prevention. Update: prevention of hepatitis A after exposure to hepatitis A virus and in international travelers. Updated recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2007;56:1080–4.

    OpenUrlPubMed
51. 51.↵
    Centers for Disease Control and Prevention. Updated recommendations from the Advisory Committee on Immunization Practices (ACIP) for use of hepatitis A vaccine in close contacts of newly arriving international adoptees. MMWR Morb Mortal Wkly Rep 2009;58:1006–7.

    OpenUrlPubMed
52. 52.↵
    Centers for Disease Control and Prevention. Use of hepatitis B vaccination for adults with diabetes mellitus: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2011;60:1709–11.

    OpenUrlPubMed
53. 53.↵
    1. Mast EE,
    2. Weinbaum CM,
    3. Fiore AE,
    4. et al

    . A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP). Part II: immunization of adults. MMWR Recomm Rep 2006;55(RR-16):1–33; quiz CE1–4.

    OpenUrlPubMed
54. 54.
    Prevention of pneumococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 1997;46(RR-8):1–24. Available at: http://www.cdc.gov/mmwr/preview/mmwrhtml/00047135.htm. Accessed May 22, 2012.

    OpenUrlPubMed
55. 55.
    1. Government of Canada PHAOC

    . Statement on the recommended use of herpes zoster vaccine: an Advisory Committee Statement—Canada Communicable Disease Report (CCDR). Vol. 0.35. ACS-1, Public Health Agency of Canada. Available at: http://www.phac-aspc.gc.ca/publicat/ccdr-rmtc/10vol36/acs-1/index-eng.php. Accessed May 22, 2012.